{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:26:17Z","timestamp":1787135177215,"version":"build-2736575974"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Transient acantholytic dermatosis, also known as Grover\u2019s disease, is an acquired pruritic eruption commonly refractory to conventional therapies. We report a case of a 76-year-old male with Grover\u2019s disease presenting with persistent pruritus and skin lesions despite multiple treatments. Upadacitinib 15\u2009mg once daily was initiated off-label and the patient reported marked improvement in pruritus within 2\u2009days of treatment and substantial reduction in lesion burden after 1\u2009month. The etiology of Grover\u2019s disease is unclear but is believed to be due in part to occlusion and damage to the sweat glands. Emerging responses to immunomodulatory therapies suggest immune dysregulation may contribute to select cases of Grover\u2019s disease. Upadacitinib, a selective Janus kinase 1 inhibitor, reduces pruritus and inflammation-associated cytokine signaling and represents a plausible therapeutic strategy. To our knowledge, this is the first reported case of Grover\u2019s disease successfully treated with Janus kinase inhibition.<\/jats:p>","DOI":"10.1177\/2050313x261463981","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:58:21Z","timestamp":1786939101000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of Grover\u2019s disease with upadacitinib: A case report"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6584-8717","authenticated-orcid":false,"given":"Eshan","family":"Arora","sequence":"first","affiliation":[{"name":"Dalhousie Medical School, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rylee","family":"Oosterhuis","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0734-1769","authenticated-orcid":false,"given":"Ashley E.","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Bellinato F Maurelli M Gisondi P et al. Clinical features and treatments of transient acantholytic dermatosis (Grover\u2019s disease): a systematic review. J Dtsch Dermatol Ges 2020; 18(8): 826\u2013833. https:\/\/doi.org\/10.1111\/ddg.14202","DOI":"10.1111\/ddg.14202"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Aldana PC Khachemoune A. Grover disease: review of subtypes with a focus on management options. Int J Detmatol 2020; 59(5): 543\u2013550. https:\/\/doi.org\/10.1111\/ijd.14700","DOI":"10.1111\/ijd.14700"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Mohamed MF Bhatnagar S Parmentier JM et al. Upadacitinib: mechanism of action clinical and translational science. Clin Transl Sci 2024; 17(1): Article e13688. https:\/\/doi.org\/10.1111\/cts.13688","DOI":"10.1111\/cts.13688"},{"key":"e_1_3_2_5_2","unstructured":"AbbVie Corporation. RINVOQ (upadacitinib) product monograph. Health Canada 2025. https:\/\/dhpp.hpfb-dgpsa.ca\/dhpp\/resource\/102847 (accessed January 2026)."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Dogra S Prarthana T Sudharani G et al. Upadacitinib in dermatology: a systematic review of mechanism current applications efficacy safety and emerging evidence. Indian J Dermatol Venereol Leprol 2026; 92: 68\u201376. https:\/\/doi.org\/10.25259\/IJDVL_133_2025","DOI":"10.25259\/IJDVL_133_2025"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Butler DC Kollhoff A Berger T. Treatment of Grover disease with dupilumab. JAMA Dermatol 2021; 157(3): 353. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5097","DOI":"10.1001\/jamadermatol.2020.5097"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Amara S Hawkins K Skaggs E et al. Efficacy of dupilumab for treatment-resistant Grover disease: a retrospective study. Br J Dermatol 2025; 192(5): 941\u2013943. https:\/\/doi.org\/10.1093\/bjd\/ljaf036","DOI":"10.1093\/bjd\/ljaf036"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Beiter K Behnam C Shields B. Recalcitrant Grover\u2019s disease successfully managed with dupilumab and naltrexone in a middle-aged woman: a case study. SKIN 2023; 7(4): 891\u2013895. https:\/\/doi.org\/10.25251\/skin.7.4.7","DOI":"10.25251\/skin.7.4.7"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Zhou MH Elston DM Morrison BW et al. Low-dose naltrexone for treatment of dermatologic conditions: a clinical review. J Am Acad Dermatol 2026; 94(1): 200\u2013207. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.028","DOI":"10.1016\/j.jaad.2025.09.028"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Hrin ML Patel PV Jorizzo JL et al. Methotrexate versus acitretin for Grover\u2019s disease refractory to topical therapies. J Cutan Med Surg 2024; 28(1): 68\u201369. https:\/\/doi.org\/10.1177\/12034754231211567","DOI":"10.1177\/12034754231211567"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Murphy MJ Junejo MH Rufin O et al. Grover disease shows type 2 immune activation and improves with dupilumab. Br J Dermatol 2025; 192(5): 939\u2013941. https:\/\/doi.org\/10.1093\/bjd\/ljaf005","DOI":"10.1093\/bjd\/ljaf005"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Mahler SJ De Villez RL Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol 1993; 29(2): 206\u2013209. https:\/\/doi.org\/10.1016\/0190-9622(93)70169-T","DOI":"10.1016\/0190-9622(93)70169-T"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Yu H Zhu J Ni X et al. Off-label use of upadacitinib in dermatology: a review. J Dermatolog Treat 2025; 36(1): 2560502. https:\/\/doi.org\/10.1080\/09546634.2025.2560502","DOI":"10.1080\/09546634.2025.2560502"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Simpson EL Silverberg JI Prajapati VH et al. Rapid itch improvement and skin clearance with upadacitinib versus placebo (Measure Up 1 and Measure Up 2) and versus dupilumab (Heads Up): results from three phase 3 clinical trials in patients with moderate-to-severe atopic dermatitis. Dermatol Ther 2025; 15(8): 2061\u20132076. https:\/\/doi.org\/10.1007\/s13555-025-01443-w","DOI":"10.1007\/s13555-025-01443-w"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261463981","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X261463981","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261463981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:46:30Z","timestamp":1787132790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X261463981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"alternative-id":["10.1177\/2050313X261463981"],"URL":"https:\/\/doi.org\/10.1177\/2050313x261463981","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X261463981"}}